How Cancer Type Affects COVID-19 Outcomes: Lennard Lee, DPhil, MRCP, BMBCh

While patients with cancer are at an increased risk of experiencing poor outcomes from COVID-19, there is significant variability in COVID-19 risk and mortality among patients with different tumor types and demographics such as age and sex, with those with hematologic malignancies facing the highest risk. In this interview with i3 Health, Lennard Lee, DPhil, MRCP, BMBCh, an Honorary Research Fellow at the University of Birmingham's Institute of Cancer and Genomic Sciences, discusses the signific...

Vivek Subbiah, MD, on Dabrafenib/Trametinib Efficacy in Biliary Tract Cancer

According to a recent study, led by Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, dabrafenib in combination with trametinib is an effective treatment option for patients with BRAFV600E -mutated biliary tract cancer (BTC). In an interview with i3 Health, Dr. Subbiah shares insights on the significance of these study results and unmet needs and future treatment in this patient population. What are the most challenging aspects of treating patients with BRAFV600E -mutated ...

Geriatric and Surgical Comanagement for Older Patients With Cancer: Armin Shahrokni, MD, MPH

Patients aged 75 years and older face an increased risk of mortality and postoperative events when undergoing surgical treatment for cancer. In a study recently published in JAMA Network Open, a research team led by first author Armin Shahrokni, MD, MPH, found that patients whose care was managed by both the surgical and geriatric teams experienced significantly better outcomes compared with those whose care was provided by the surgical team alone. In this interview with i3 Health, Dr. Shahrokni...

Hans C. Lee, MD: FDA Approval of Belantamab Mafodotin-blmf for R/R Multiple Myeloma

For patients with relapsed or refractory (R/R) multiple myeloma (MM), a new treatment has just been recently FDA approved: belantamab mafodotin-blmf (BLENREP®, GlaxoSmithKline). In an interview with i3 Health, Hans C. Lee, MD, of The University of Texas MD Anderson Cancer Center, speaks about the significance of this approval and what the future may look like on treating these patients. What are the most challenging aspects of treating patients with R/R MM? Hans C. Lee, MD: While there have been...

Tafasitamab/Lenalidomide for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Gilles Salles, MD, PhD

Recently, the FDA granted accelerated approval to tafasitamab-cxix (Monjuvi®, MorphoSys US Inc.) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplantation. In this interview with i3 Health, Gilles Salles, MD, PhD, principal investigator of the phase 2 L-MIND trial, on which the approval was based, discusses the significance of the approval, adverse events of note with tafasitamab/lenal...

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.

Cron Job Starts